FDA Approves MEKINIST — Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation has received FDA approval for MEKIST (trametinib) dimethyl sulfoxide, marking an update to an existing product line. This approval retains the oral drug's status as a vital option for targeted cancer treatments, directly impacting the manufacturer's strategic positioning and therapeutic portfolio.